Assessing HIV Vulnerability and the Use of Oral Pre-Exposure Prophylaxis (PrEP) in Injecting Drug Users in Nairobi: A Cross-Sectional Analysis - Takeaways - MDSpire

Assessing HIV Vulnerability and the Use of Oral Pre-Exposure Prophylaxis (PrEP) in Injecting Drug Users in Nairobi: A Cross-Sectional Analysis

  • By

  • Cosmas Mugambi

  • Loice Mbogo

  • William Sinkele

  • Esther Gitau

  • Tecla Temu

  • Carey Farquhar

  • David Bukusi

  • John Kinuthia

  • Aliza Monroe-Wise

  • January 5, 2026

  • 0 min

Share

  • 1

    HIV prevalence among people who inject drugs (PWID) in Kenya was estimated at 18.7% in 2021, highlighting significant health disparities.

  • 2

    Pre-exposure prophylaxis (PrEP) can reduce HIV acquisition risk by 99% from sex and 74% from drug injection, yet awareness among PWID remains low.

  • 3

    Provider-level barriers, including stigma and misconceptions about drug users, contribute to the low uptake of PrEP among PWID in Kenya.

  • 4

    The study aimed to assess HIV vulnerability and PrEP knowledge among PWID in Nairobi, addressing gaps in research and intervention strategies.

  • 5

    Improving PrEP uptake among PWID requires understanding their specific risks and needs, as current outreach efforts primarily target other key populations.

Original Source(s)

Assessing HIV Vulnerability and the Use of Oral Pre-Exposure Prophylaxis (PrEP) in Injecting Drug Users in Nairobi: A Cross-Sectional Analysis

  • by Cosmas Mugambi, Loice Mbogo, William Sinkele, Esther Gitau, Tecla Temu, Carey Farquhar, David Bukusi, John Kinuthia, Aliza Monroe-Wise

  • January 5, 2026

Related Content

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.

Tracking Key Mental Health and Substance Use Policy Actions Under the Trump Administration

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical